Negative impact on 2017 profits.
Profit of Hungary's leading drugs maker plunges.
Earnings report expected to show profit contraction.
Government to support the sector.
One of key products under EMA investigation.
After robust Q3 figures.
Profit greatly beats expectations.
Regardless of rouble trouble.
Signs exclusive distribution agreement with Prima-Temp.
For the commercialisation of novel drug in Europe, Latin America and other markets.
As of 1 August.
Despite profit plunge.
Earnings report to be published this week.
Key drug to hit shelves in Western Europe soon.
500 employees to be sacked from the Gödöllő plant.
Operating profit margin also seen higher.
Leading pharma reports robust Q1 results.
Robust quarter projected.
18 billion forint investment at the door.